How Much Merck Do You Really Get Through 3 ETFs?

Simply Wall St · 1d ago

Owning Merck directly means you carry company specific issues by yourself, such as a dividend that Simply Wall St says is not well covered by earnings, or profit margins that Simply Wall St notes are much slimmer than last year. Holding Merck inside a fund that also owns other healthcare businesses spreads out how much those Merck specific swings can move your portfolio. It also reduces the impact of any positive surprise from Merck on its own.

The fresh twist is clinical news. Merck just reported that its TroFuse-015 study for sacituzumab tirumotecan in advanced cancer of the stomach and oesophagus met its main goal by helping patients live longer, with safety in line with earlier work. For investors who want Merck inside a broader mix, XLV, VHT and IHE offer different ETF routes to do that.

Fund Merck weight Rank in fund by weight 5-year annualised return after fees Fee Assets
State Street Health Care Select Sector SPDR ETF (XLV) 5.32% #5 of 64 7.8% 0.08% US$50.57 billion
Vanguard Health Care ETF (VHT) 4.77% #5 of 417 6.8% 0.09% US$23.70 billion
iShares U.S. Pharmaceuticals ETF (IHE) 4.15% #7 of 56 12.3% 0.37% US$1.74 billion

Rather choose individual stocks than a fund? Explore 35 high quality undervalued stocks.

State Street Health Care Select Sector SPDR ETF (XLV)

XLV leans heavily toward large US healthcare businesses, with pharmaceuticals at 37.2% of the portfolio and sizeable slices in biotechnology, equipment, and life sciences tools. Merck is the fifth largest holding at 5.32%, so each US$1,000 in XLV gives you about US$53 in Merck alongside bigger stakes in Eli Lilly and Johnson & Johnson. Those other holdings pull some of your healthcare exposure toward areas like diabetes treatments, consumer health products, medical devices, and research tools rather than one drug portfolio.

One flagged issue for Merck is that its 2.56% dividend is not well covered by earnings. XLV spreads that single company payout risk across dozens of healthcare stocks, so your income stream depends on a wider set of pharmaceutical, biotech, equipment, and managed care dividends. You are still tied to the health of the US healthcare sector overall, which leaves you relying on a single industry rather than a mix that includes other parts of the economy.

Not every stock inside XLV is priced the same way. Find out how many of XLV's holdings look undervalued.

Vanguard Health Care ETF (VHT)

AbbVie, Johnson & Johnson and Eli Lilly shape most of what you own in VHT, alongside a broad mix of pharmaceuticals at 33.7%, biotechnology at 24.1%, and meaningful slices in health care equipment, tools, managed care and services. Merck is the fifth largest position at 4.77%, so roughly US$48 of every US$1,000 goes into Merck, and XLV holds a slightly larger slice. VHT closely resembles XLV but spreads its money across 417 stocks, which means a long tail of smaller holdings that XLV does not reach.

Large one off items can sway Merck’s reported earnings, which can make the stock’s results vary from year to year. VHT partly cushions that by tying most of the outcome to other healthcare groups whose profits depend on different product lines and customer bases. However, everything in the fund still responds to conditions in the same broad sector, so this structure provides more varied healthcare exposure than holding Merck alone.

Compare how far VHT is ahead of or behind the market across six periods

iShares U.S. Pharmaceuticals ETF (IHE)

You get a modest slice of Merck in IHE, about 4.15% of the portfolio, so roughly US$42 of every US$1,000 you invest. Most of your result rides on other pharmaceuticals instead. Eli Lilly and Johnson & Johnson together account for 48.8% of the ETF, which concentrates your healthcare exposure in a few large drug makers. About 36% of IHE overlaps XLV, and the rest tilts toward other US pharmaceutical stocks that XLV does not own in size, while charging a higher 0.37% fee compared with XLV at 0.08%.

Merck’s profit margins sit at 3.6% compared with 29.6% last year, which leaves investors exposed to swings in how efficiently its drug portfolio turns revenue into earnings. IHE only softens that company specific issue to a degree because almost all of its 99.5% exposure is still in pharmaceuticals, so weak profitability at one large drug business can be partly offset by others whose results depend on different therapies and markets, but sector wide pressure on pricing would still hit much of this ETF at the same time.

See what you'd actually own if you bought IHE, from its 56 positions to how much sits in the top 10.

Merck through funds means choosing your mix

In all three ETFs, Merck is a modest slice, between about US$42 and US$53 for every US$1,000 you put in, so the real question is what you want around it. XLV gives you that larger Merck stake at the lowest fee, US$8 a year on a US$10,000 holding, with healthcare equipment, tools and managed care alongside pharmaceuticals and biotechnology. VHT looks similar by industry but owns 417 stocks instead of the 64 in XLV, which spreads your healthcare exposure across many more businesses.

IHE is different. Almost everything sits in pharmaceuticals, and its cost is higher at US$37 a year on US$10,000, so your decision is whether a focused drug-heavy portfolio is worth that, given risks such as Merck’s weaker profit margins and clinical news such as the recent positive trial result. The first choice is simple: do you want a broad healthcare mix with Merck in the middle, or a concentrated allocation to drug makers with Merck as one of several large positions?

Eli Lilly is the largest holding in both XLV and VHT, so you'd own it either way. Check whether Eli Lilly trades above or below its fair value.

Fund data as of 31 October 2026. Portfolio holdings as of 31 October 2026.